Navigation Links
First Human Study to Show 'Sun Chlorella A' Supports Heart Health
Date:3/30/2009

RICHMOND, Va., March 30 /PRNewswire/ -- A new study, published in the Journal of Medicinal Food, showed that consumption of as little as 8 grams (1/3 ounce) of "Sun Chlorella A" daily resulted in noticeable reductions in body fat percentage, serum total cholesterol, and fasting blood glucose levels.

For a 12-week period, 34 participants ingested four grams of "Sun Chlorella A" tablets each morning and evening. Seventeen subjects were healthy; the other 17 were at high risk for developing lifestyle-related illnesses.

Both groups had a decrease in body fat percentage and total serum cholesterol. However, the high-risk group also experienced lowered blood glucose, possibly due to improved insulin sensitivity induced by adding Chlorella to the daily diet.

Heart disease and stroke are the number one and three causes of death for both men and women in the U.S. Risk factors include elevated serum cholesterol, high blood pressure, a sedentary lifestyle, unhealthy diet, smoking, obesity, and hyperglycemia.

According to Mark Drucker, M.D., "Heart health is important to everyone. Remember, our hearts must be nourished to stay healthy. With protein, minerals, vitamins and fiber, Sun Chlorella is what I take, and what I recommend to all my patients."

Chlorella is a single-cell, fresh water green alga. Past research has shown that Chlorella is effective for immune activation, growth promotion, and detoxification of heavy metals and pesticides. However, unlike this recent study, most of the prior research used laboratory animals.

Dr. Randall E. Merchant earned his Doctoral and Master of Sciences degrees from the University of North Dakota. Dr. Merchant is a Professor of Anatomy and Neurosurgery at Virginia Commonwealth University, and has conducted several clinical investigations on the role of nutrition on overcoming the effects of ce
'/>"/>

SOURCE Randall E. Merchant, Ph.D.
Copyright©2009 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Mass. and TORONTO , ... ) (OTCBB: GNBT) today announced three presentations demonstrating the ... by its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ... meeting of the American Society of Clinical Oncology (ASCO) ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
(Date:5/22/2013)... and TORONTO , May 22, 2013 ... that John Mon , Chief Operating Officer, ... on Thursday, May 30, 2013 in New York ... The Company,s presentation is scheduled to begin at 4:00 ... To access the webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... Trubion,s Proprietary ... Product Candidate, SBI-087 for RA Expands Trubion,s Family of Customized, Differentiated ... Product Candidates, ... has initiated a Phase 1/2,clinical trial of TRU-016, the company,s lead proprietary Small Modular,ImmunoPharmaceutical ...
... Encouraging Response in CF Patients - Results Validate ... March 27 The Cystic Fibrosis Foundation,announced today that ... defect in CF, showed promising results in an ongoing ... mutation of CF. The drug is,being developed by Vertex ...
Cached Medicine Technology:Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 2Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 4Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 5Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3
(Date:5/22/2013)... 2013 Garcinia cambogia select is a dual ... inhibiting the extra fat being stored in the body. For ... intake. This fat burner helps people in this regard by ... overeating. Basically it does this by secreting a hormone serotonin ... them away from emotional overeating. In this way, it keeps ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 On ... the presiding judge for the New York City ... brought by the Long Island Railroad (“LIRR”) against ... resident, who, according to court documents, was diagnosed ... exposure. , According to court documents, the injured ...
(Date:5/22/2013)... these findings in the current online edition of ... study could open up new possibilities of early ... tackle diseases before the patient,s nervous system is ... of genetic diseases of the cerebellum and other ... limited control of their muscles. They also suffer ...
(Date:5/22/2013)... In the long run, encouraging a baby to finish the ... than good. , Though the calories soon burn off, a ... Gibbs and Renata Forste found that clinical obesity at 24 ... "If you are overweight at age two, it puts you ... into middle childhood and adolescence and as an adult," said ...
(Date:5/22/2013)... NY (PRWEB) May 22, 2013 ... now have access to Adapt Courseware’s new ... in an adaptive framework that responds based on ... Courseware , the provider of comprehensive adaptive online ... is continuing to develop introductory level general education ...
Breaking Medicine News(10 mins):Health News:Garcinia Cambogia Reviews Released Online for Fast Weight Loss Solution with Offer of Extra 3 Month Supply 2Health News:New York Mesothelioma Lawyers Defeat LIRR’s Motion for Summary Judgment 2Health News:New York Mesothelioma Lawyers Defeat LIRR’s Motion for Summary Judgment 3Health News:New York Mesothelioma Lawyers Defeat LIRR’s Motion for Summary Judgment 4Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Overeating learned in infancy, study suggests 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3
... Corp. ("Echo" or the "Company") (OTC Bulletin Board: ... meeting of stockholders today,that the polls will remain ... vote on the proposed merger transaction with XLNT,Veterinary ... forth in the,proxy statement/prospectus previously mailed to Echo ...
... The California Nurses,Association/National Nurses Organizing Committee today ... liver transplant one week earlier for,17-year-old Nataline Sarkisyan, ... relented and agreed to the procedure following a ... physicians, including the surgical director of,the Pediatric Liver ...
... EPA, National Contest Urges Young People to Promote ... National Safety,Council has named the winners of its ... the United States Environmental Protection,Agency. First-place winner is ... Arts & Science in Hollywood, Florida; second-place winner ...
... of a songbird may appear effortless, but his elocutions ... youth and maintained throughout adulthood. His tune has virtually ... the motor performance of top athletes and musicians. Yet, ... songbirds and humans. Now, scientists think they know why. ...
... Partnership Co-led by Founder and CEO Dennis Gillings, Bain ... ... Dec. 21 Quintiles,Transnational Corp. today announced the formation of a ... current Chairman and CEO Dennis Gillings, CBE, and the management team.,Gillings ...
... MASI ), the inventor of Pulse CO-Oximetry and ... it is scheduled to,present at the 26th Annual JPMorgan ... CA on Monday, January 7, 2008 at 8:30 a.m. ... de Raad, Executive Vice,President and CFO, will be presenting., ...
Cached Medicine News:Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 5Health News:RN's Statement on Death of Nataline Sarkisyan: 'CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago' 2Health News:National Safety Council Names Winners of Radon Poster Contest 2Health News:Songbirds offer clues to highly practiced motor skills in humans 2Health News:Songbirds offer clues to highly practiced motor skills in humans 3Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 2Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 3Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 4Health News:Masimo to Present at 26th Annual JPMorgan Healthcare Conference 2
Malaria Pf. Assay Range...
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: